T he articles by Vaishnavi et al. (1) and Vlassenko et al. (2) in PNAS demonstrate regional variation in aerobic glycolysis vs. oxidative phosphorylation in the human brain and then link aerobic glycolysis to amyloid β (Aβ) deposition on the basis of concordant spatial distributions in Alzheimer's disease (AD). As referenced in these articles, the molar ratio of O 2 to glucose consumption by the brain is never 6 (the ratio for complete oxidation of glucose to CO 2 and H 2 O). Because the experimentally determined molar ratio is normally ≈5.3, the major portion of glucose flux proceeds through the tricarboxylic acid (TCA) cycle to meet the high ATP demands of the brain, as well as other TCA cycle functions. The term "aerobic glycolysis," as defined by the authors, refers to flux from glucose to pyruvate without entering the TCA cycle, as well as glucose providing substrates for the pentose phosphate shunt and glycogen synthesis, in conditions whereby oxygen availability is not limiting. Although much less energy efficient than mitochondrial oxidative phosphorylation (36 ATP/glucose), aerobic glycolysis (2 ATP/glucose) can rapidly provide ATP and substrates for biosynthetic pathways.
Raichle and colleagues were the first to clearly demonstrate that task-based activation of local regions of the human brain associated with increases in glucose metabolism determined with 2-deoxy-2-[
18 F] fluoro-D-glucose (FDG) and PET (3) occur with little to no increases in oxygen metabolism, even though local availability of oxygen is sufficient for oxidative phosphorylation (references in ref. 1). These findings indicate that, in execution of these tasks, the involved brain tissue switches to aerobic glycolysis.
These "switch points" that alter glucose metabolic flux through various biochemical pathways occur in a number of transitions from one cellular state to another, in normal and pathologic conditions. As stated by the authors, the oldest and most cited switch point in aerobic glycolysis is the "Warburg effect," as part of malignant transformation. In further support of the examples cited by Vaishnavi et al. (1) , other demand-driven transitions to aerobic glycolysis have been demonstrated, exemplified in the developing embryo (4), the transition from the resting state to activation in the immune system (5, 6) , and during viral infection (7).
Vaishnavi et al. (1) and Vlassenko et al. (2) show that higher levels of aerobic glycolysis are concentrated in the default mode network (DMN), an anatomically defined brain network-involving the medial temporal lobe and the medial prefrontal subsystems that converge for integration in the posterior cingulate gyruspreferentially active when individuals Brain regional correlations between markers for amyloid tau deposition, glucose hypometabolism, and neuronal losses and corresponding alterations in neuropsychiatric measures were demonstrated in humans with AD and mild cognitive impairment (MCI) (10) . These results strengthened earlier suggestions that clinical symptoms characteristic for AD stem from the disruption of major neuronal circuits caused by the extensive loss of neurons forming these circuits associated with early pathological Aβ and τ deposition initially affecting the entorhinal cortex. With advancing stages of AD, the death of cortical neurons increasingly spreads to regions beyond the hippocampus, one of the critical initial sites of neuronal damage. As part of disease progression, glucose metabolic deficits become increasingly widespread, with worsening in clinical parameters of AD. This specific pattern of regional hypometabolism, as assessed with FDG PET, distinguishes AD from other pathologic processes that can cause dementia, as evidenced by autopsyconfirmed diagnoses (11 (12) . In at least two studies, negative [ 11 C]PIB results were reported in AD patients with positive autopsy evidence of amyloid aggregates in the brain (13, 14) . In addition, [ 11 C]PIB has not shown a pattern of accumulation consistent with progressive Aβ accumulation across the trajectory of the disease, as would be expected from autopsy data (15) . For example, MCI patients seem to group into two categories: [ 11 C]PIB binding pattern that is negative (similar to controls) or positive to the level of signal intensity and cortical localization comparable to symptomatic AD patients (16) . Regarding the latter, this has been interpreted as due to the accumulation of AD-level amyloid load by the time the (20) . SULT1E1 is an enzyme involved in estrogen homeostasis that is present in the rat brain (21) and other species. In the rat brain, for example, there is SULT1E1-mediated transformation of [ 11 C]PIB to its 6-Osulfate product that is trapped in tissue and accumulates in proportion to the rate of this enzyme-mediated reaction (20) , similar to the way hexokinase mediates FDG accumulation as its 6′-phosphate product (3). [
11 C]PIB-6-sulfate has also been determined to be present in human plasma as a major peripheral metabolite, as an indication that [ 11 C]PIB metabolic transformation is also possible in humans.
Estrogens are known to exert neuroprotective effects (22) , and increased expression of SULT1E1 is also known to suppress estrogen effects, which are associated with inflammation in various tissues, including in human cancers. Considerable evidence gained over the past decade has implicated neuroinflammation as a possible prelude and consequence of AD pathology, with components including microglia and astrocytes as well as elevated cytokines and chemokines (23) .
Further biochemical experiments will be needed to establish the reaction mechanisms underlying the retention of [ 11 C]PIB in the human brain in vivo, and from this, to explore the mechanisms that underlie the spatial correspondence of aerobic glycolysis and the biochemical process reflected in [
11 C]PIB images.
